WHO approves Japan-made dengue vaccine – The Times of India

WHO approves TAK-003 (Qdenga) as 2nd dengue vaccine for children aged 6-16 in high-burden areas. Takeda in talks to launch in Indi... Read More WHO approves TAK-003 (Qdenga) as 2nd dengue vaccine for children aged 6-16 in high-burden areas. Takeda in talks to launch in India. Panacea Biotec & Serum Institute collaborate on indigenous vaccine trials. Read Less World Health Organization has approved a second dengue vaccine, TAK-003 (Qdenga), for use among children aged 6-16 years in places with high case burden and transmission intensity. The vaccine, developed by Japanese pharma giant Takeda, can be administered in a two-dose schedule with a three-month interval between doses . The first dengue vaccine to be approved by WHO was Sanofi Pasteur's Dengvaxia. Both dengue vaccines are at present not available in India. But, sources said, Takeda is in talks with an Indian firm to launch TAK-003 (Qdenga) in the country. Also, Panacea Biotec and Serum Institute of India - the two leading vaccine manufacturing firms in India - are collaborating to conduct human trials of an indigenous dengue vaccine that has already successfully completed initial trials.

Popular from World

'A wake-up call to West': Europe on edge after assassination attempt on Slovakian PM Robert Fico

France: Troops deployed, TikTok banned as deadly unrest rocks New Caledonia

'India landed on moon, while we ... ': Pakistani lawmaker highlights lack of amenities in Karachi

Gujarati careworkers face destitution and deportation in Britain after being scammed

After samosas, golgappas appears on White House menu

end of article

Read the original:

WHO approves Japan-made dengue vaccine - The Times of India